Unprecedented Sensitivity

This noninvasive test detects over 95% of advanced melanomas and is up to 1,000-fold more sensitive than other testing methods, enabling it to detect very low levels of cancer.

Improves the Prognosis

The sensitivity of the test enables patients to start treatment at an early stage of their disease, thus improving the prognosis and potentially allowing them to receive lower and less toxic doses of chemotherapy.

A Versatile Test

The test could be used for the detection of cancers other than melanoma. These include cancer of the pancreas, ovary, lung, colon, and breast.

Quantitative Measurement

Rather than detect only the presence or absence of malignant cells, the test is quantitative. It yields measurement data for metastatic cancer cells that can be used in determining a patient’s treatment and monitoring individual response to therapy.

File Number: 262 

Web site: http://www.uvminnovations.com/diagnostics.html

Other Information:

Commercialization

We anticipate a low cost to develop and produce a commercial application of this technology. Entry into the heathcare market should be rapid as the technology does not directly involve a therapeutic intervention.

If commercialized by a medical laboratory, the test could be ordered by healthcare providers. The only specimen required would be a simple blood or tissue sample.

Next Steps

Clinical studies will determine the sensitivity and specificity of the test in patient populations.